Locana develops RNA-targeting gene therapies specifically designed to treat severe neurodegenerative, neuromuscular, and retinal diseases. By directly addressing the underlying genetic causes of these conditions, Locana aims to improve patient outcomes and quality of life.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many severe neurodegenerative, neuromuscular, and retinal diseases lack effective treatments because they are caused by complex or hard-to-reach genetic mutations. Traditional gene therapies may not be able to address these underlying genetic causes, leaving patients with limited options.
Solution
Locana Bio is developing RNA-targeting gene therapies designed to directly address the genetic drivers of severe neurodegenerative, neuromuscular, and retinal diseases. Their approach aims to correct or silence disease-causing genes at the RNA level, offering a potential therapeutic avenue for conditions with limited treatment options. By targeting RNA, Locana's therapies seek to provide more precise and effective interventions for patients suffering from these debilitating diseases.
Target Audience
The primary target audience includes patients suffering from severe neurodegenerative, neuromuscular, and retinal diseases, as well as their families and healthcare providers.
Features
- RNA-targeting technology for precise gene modulation
- Focus on severe neurodegenerative, neuromuscular, and retinal diseases
- Designed to address underlying genetic causes
- Potential for improved patient outcomes and quality of life